NCT03328897 - Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria | Biotech Hunter

Enrollment

418

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

July 23, 2019

Study Completion Date

September 24, 2019

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

Omalizumab

injection of 150mg or 300 mg

DRUG

Placebo

Injection of placebo

Trial Locations (27)

100034

Novartis Investigative Site, Beijing

100039

Novartis Investigative Site, Beijing

100050

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

110000

Novartis Investigative Site, Shenyang

150001

Novartis Investigative Site, Harbin

200025

Novartis Investigative Site, Shanghai

200040

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

210042

Novartis Investigative Site, Nanjing

215006

Novartis Investigative Site, Suzhou

310003

Novartis Investigative Site, Hangzhou

310006

Novartis Investigative Site, Hangzhou

310016

Novartis Investigative Site, Hangzhou

350025

Novartis Investigative Site, Fuzhou

400011

Novartis Investigative Site, Chongqing

400038

Novartis Investigative Site, Chongqing

410008

Novartis Investigative Site, Changsha

430022

Novartis Investigative Site, Wuhan

430030

Novartis Investigative Site, Wuhan

510000

Novartis Investigative Site, Guangzhou

510630

Novartis Investigative Site, Guangzhou

530021

Novartis Investigative Site, Nanning

610041

Novartis Investigative Site, Chengdu

830001

Novartis Investigative Site, Ürümqi

Unknown

Novartis Investigative Site, Wuxi